Canopy Growth (CGC) Liabilities from Discontinued Operations (2022 - 2023)
Canopy Growth's (CGC) quarterly Liabilities from Discontinued Operations came in at 1463515.58 in Q3 2023, down 42.1% quarter-over-quarter from 2527542.48 in Q1 2023.
Canopy Growth (CGC) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends
Canopy Growth has disclosed Liabilities from Discontinued Operations across 2 years of filings, most recently posting 1463515.58 for Q3 2023.
- Liabilities from Discontinued Operations for Q3 2023 came in at 1463515.58, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was 1463515.58 (changed N/A YoY), and the FY2023 annual result was 2527542.48, changed N/A from the prior year.
- Liabilities from Discontinued Operations came in at 1463515.58 for Q3 2023 at Canopy Growth, down from 2527542.48 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 6992784.31 in Q4 2022 to a low of 1463515.58 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Canopy Growth | 11.38 Mn | -137.31 Mn | 15.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 1.46 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Mar 31, 2023 | 2.53 Mn |
| Mar 31, 2023 | 2.53 Mn |
| Dec 31, 2022 | 6.99 Mn |
| Dec 31, 2022 | 6.99 Mn |